Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20276702 | 0.83 | LMNA (0.47) | IRAK4BRD9GSK3BDYRK1ACNR2 | |
| SCHEMBL31437491 | 0.82 | LMNA (0.40) | IRAK4BRD9GSK3BDYRK1ACNR2 | |
| SCHEMBL22857998 | 0.81 | IRAK4 (0.45) | IRAK4BRD9GSK3BDYRK1ACNR2 | |
| SCHEMBL27457955 | 0.79 | ATR (0.39) | IRAK4BRD9GSK3BDYRK1ACNR2 | |
| SCHEMBL22857997 | 0.79 | CNR2 (0.53) | IRAK4BRD9GSK3BDYRK1ACNR2 | |
| SCHEMBL27457954 | 0.79 | GSK3B (0.40) | IRAK4BRD9GSK3BDYRK1ACNR2 | |
| SCHEMBL18215077 | 0.79 | ALOX5 (0.42) | IRAK4BRD9GSK3BDYRK1ACNR2 | |
| SCHEMBL31439890 | 0.78 | GSK3B (0.39) | IRAK4BRD9GSK3BDYRK1ACNR2 | |
| SCHEMBL31555029 | 0.78 | IRAK4 (0.41) | IRAK4 | |
| SCHEMBL18138349 | 0.77 | L3MBTL1 (0.39) | IRAK4BRD9GSK3BDYRK1ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4095138-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2022-11-30 | — | — | EP | disclosed |
| EP-3555093-B1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-09-21 | — | — | EP | disclosed |
| CN-110072863-B | RIP1 kinase inhibitors and methods of use | 豪夫迈·罗氏有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11072607-B2 | Inhibitors of RIP1 kinase and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-11072607-B2 | Inhibitors of RIP1 kinase and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072607-B2 | Inhibitors of RIP1 kinase and methods of use thereof | RIPK1, RIPK2, RIPK4 | IRAK4 49/4885BRD9 1531/4885GSK3B 365/4885 |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | RIPK1, RIPK2, RIPK4 | IRAK4 49/4885BRD9 1531/4885GSK3B 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.